While reporting financial results for the first quarter on Thursday, Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2026.
For fiscal 2026, the company continues to project adjusted earnings in the range of about $6.05 to $6.35 per share on worldwide total revenues between about $46.0 billion and $47.5 billion.
The company also said it continues to expect total Worldwide Eliquis revenues to increase in 2026, when compared to 2025 by 10 to 15 percent.
In Thursday's pre-market trading, BMY is trading on the NYSE at $57.61, up $0.02 or 0.03 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.